Filing Flows › Co-Diagnostics (CODX) › Q2 2026 › vs Q1 2026
Co-Diagnostics (CODX) Q2 2026 vs Q1 2026 (quarter over quarter)
Co-Diagnostics's revenue rose $20K (+14%) from $146K in Q1 2026 to $166K in Q2 2026.
Co-Diagnostics, Q2 2026: revenue $166K (+2% year over year), net loss $6.3M, operating cash flow −$7.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $166K | $146K | $20K | +14% |
| Net loss | $6.3M | $9.1M | −$2.9M | -31% |
| Costs & expenses | $6.4M | $9.4M | −$2.9M | -31% |
| Operating costs | $6.4M | $9.4M | −$3.0M | -32% |
| Interest & other, net | $64K | −$69K | $133K | — |
| Income tax | $19K | $1K | $19K | 37× |
| Cost of revenue | $45K | $194K | −$148K | -77% |
| Research & development | $4.2M | $5.9M | −$1.8M | -30% |
| Sales & marketing | $467K | $468K | −$1K | -0.3% |
| General & admin | $1.5M | $2.5M | −$1.0M | -40% |
| Other operating costs | $202K | $255K | −$54K | -21% |
| Operating cash sources | $7.6M | $8.3M | −$752K | -9% |
| Depreciation & amortization | $202K | $255K | −$54K | -21% |
| Share-based compensation | $214K | $219K | −$5K | -2% |
| Cash used in operations | $7.2M | $7.8M | −$693K | -9% |
| Net loss absorbed | $6.3M | $9.1M | −$2.9M | -31% |
| Working capital & other | $1.3M | −$819K | $2.1M | — |
Questions
How much did Co-Diagnostics's revenue grow quarter over quarter in Q2 2026?
Co-Diagnostics's revenue rose $20K (+14%) from $146K in Q1 2026 to $166K in Q2 2026.